

Antiproliferative and cytotoxicity effects of aluminium (iii) phthalocyanine chloride tetra sulphonic acid-mediated photodynamic therapy on oesophageal cancer

O C Didamson¹, R Chandran¹ and H Abrahamse¹

Laser Research Centre, Faculty of Health Sciences, University of Johannesburg P. O. Box 17011, Doornfontein 2028, South Africa

E-mail: habrahamse@uj.ac.za

Abstract. Oesophageal cancer is an aggressive and lethal malignancy accounting for the eighth leading cause of cancer and sixth cause of cancer-related death globally. Conventional treatments for oesophageal cancer are characterised by suboptimal efficiency resulting in treatment resistance and relapse. Photodynamic therapy (PDT), a non-invasive modality, has emerged as a potential alternative cancer therapy. Growing evidence has shown that aluminium (III) Phthalocyanine Chloride Tetra sulfonic Acid (AlPcS₄Cl) is a promising photosensitiser in PDT owing to its photochemical and photophysical features. This study examined the antiproliferative and cytotoxic impacts of AlPcS₄Cl-mediated PDT in an oesophageal cancer cell line (HKESC-1). The HKESC-1 cells were grown and maintained in a culture medium incubated at 37° C, with 5% CO₂ and 85% humidity. The cells were treated with increasing dose concentrations of AlPcS₄Cl and irradiated at a fluence of 5 J/cm² using a diode laser at 673.2nm wavelength. The cellular activities following 24 hours post-PDT were evaluated using microscopy and biochemical tests to determine the response of HKESC-1 cells to treatments. Results from treated cells displayed a dose-dependent response as shown by the significant morphologic changes, increased cytotoxic damage, and reduced cell viability and proliferation. Fluorescent microscopy revealed that AlPcS₄Cl was internalised in the mitochondria and lysosomes, suggesting the possible cell death pathways. The study showed that AlPcS₄Cl mediate PDT is an efficient treatment modality for oesophageal cancer. Further research on the mechanism of cell death pathways in oesophageal cancer could enhance and translate the potential application of AlPcS₄Cl mediated PDT of cancer in clinical settings.

1. Introduction

Oesophageal cancer is an aggressive and lethal malignancy accounting for the eighth leading cause of cancer and the sixth cause of cancer-related death worldwide [1]. Conventional treatments for oesophageal cancer consist of surgery, chemotherapy, and radiotherapy [2], and recently immunotherapy has also been employed for the treatment of oesophageal cancer [2, 3]. However, these conventional therapies are characterised by suboptimal efficiency resulting in treatment resistance, relapse, and severe adverse effects. Also, not all patients are eligible for immunotherapy. Photodynamic therapy (PDT), a non-invasive modality, has emerged as a potential alternative cancer therapy for either curative or palliative purposes. PDT has gained much attention due to its effectiveness, limited toxicity, compatibility with other treatments, can be repeated several times, and cost-effectiveness [4]. PDT is made up of three crucial components, photosensitiser (PS), light and oxygen. The PS, a light-activated agent, is first administered and internalised within the tumour cells, then irradiated with

suitable light at a particular wavelength, resulting in reactive oxygen species (ROS) generation, oxidative stress, damage to cellular organelles /membranes and ultimately the death of cancer cells [5]. Growing evidence indicates that Aluminium (III) Phthalocyanine Chloride Tetra Sulfonic Acid (AlPcS₄Cl) is a promising photosensitiser in PDT for various tumours due to its distinct photochemical and photophysical features [6]. However, its cellular impacts on HKESC-1 oesophageal cancer cells are limited. This study examined the antiproliferative and cytotoxic impacts of AlPcS₄Cl-mediated PDT in an oesophageal cancer cell line (HKESC-1).

2. Method

2.1. Cell culture

A human oesophageal cancer cell line (HKESC-1) used in this study was purchased from Cellonex (South Africa), a distributor of AddexBio. HKESC-1 cells were maintained in T75 culture flasks in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, D5796) with the addition of 10% Fetal Bovine Serum (FBS) (Biochrom, S0615), 1mM sodium pyruvate 1% antibiotic: 0.5% Amphotericin B and 0.5% Penicillin-streptomycin. The cells were maintained under 5% CO₂, 37°C and 80% humidity.

2.2. Photodynamic Treatment

Experimental and control cells were cultured with a seeding density of 5×10^5 in culture Petri dishes of 3.4 cm² diameter until cells attain 90 percent confluence. The cells then received different concentrations of the PS (AlPcS₄Cl) (1.25, 2.5, 5, 10 & 20µM) and were incubated for four hours at 37°C and 5% CO₂ to allow cellular localisation of the PSs. After incubation, the cells were subjected to irradiation using a continuous semiconductor diode laser (Oriol Corporation) at 673 nm and 5 J/cm² fluency. After that, the irradiated culture plates were incubated for 24 hours before biochemical assays were conducted.

2.3. Cell Morphology

Cellular morphological changes were visualised and examined with an inverted light microscope (Wirsam, Olympus CKX41Q4), and images taken with an Olympus digital camera.

2.4. Cellular Proliferation Assay

Cellular proliferation examination was conducted using the CellTiter-Glo® 3D luminescence reagent (Promega, G968A) to determine the level of ATP in live cells. Briefly, 50µL cell suspension and 50µL of the reconstituted reagent were added into an opaque-walled 96 well plate and carefully mixed. The plate was placed on a shaker for 2 minutes to facilitate lysis and kept in the dark at ambient temperature for 10 minutes. The ATP luminescence generated was quantified using the PerkinElmer, VICTOR Nivo™.

2.5. Viability

Cell viability assay was performed using the Trypan blue exclusion test to determine the proportion of live cells. Ten microlitres of 0.4% Trypan blue (Sigma Aldrich, T8154) were added to an equivalent volume of cell suspension and mixed properly. Then, the 10µL volume was pipetted to a counting chamber slide and slotted into an automated cell counter (Countess®).

2.6. Cytotoxicity

A cytotoxicity assay was conducted to measure the lactate dehydrogenase (LDH) enzyme released by the damaged cell membrane. The test was achieved using the Cyto Tox 96® Non-Radioactive Cytotoxicity assay (Promega, G179A). Briefly, 50µL of reconstituted substrate mix and 50µL of cell suspension were added into a 96 multi-well plate and mixed. The plate was wrapped with foil and kept in the dark for 30 minutes at 25°C. The colour produced was measured using PerkinElmer, VICTOR Nivo™ at an absorbance of 490nm.

2.7. Data Analysis

All results collated and analysed using GraphPad Prism (v5). All experiments were conducted at least two times and in biological triplicates ($n=3$). The mean values of test groups were evaluated in relation with the mean value of control cells. One-way ANOVA was employed, and a statistical significance was defined as $p < 0.05$ (*), $p < 0.01$ (**), and $p < 0.001$ (***)

3. Result and Discussion

3.1. Cellular Morphology

We studied the effect of AlPcS₄Cl-PDT on the morphology of HKESC-1 cells by examining the cellular alterations after incubation with varying concentrations of AlPcS₄Cl (1.25-20 μ M) pre and post irradiation. Our findings from cells without irradiation showed that AlPcS₄Cl do not have a cytotoxic effect on HKESC-1 cells compared to the untreated control (Figure 1A). No morphological changes were observed in the absence of light. No differences were seen between the control cells with no PS and cells with PS. However, the irradiated cells with AlPcS₄Cl at 5 J/cm² showed significant cellular morphological changes (Figure 1B). Morphological impairments showed 24 hours after treatment was shrinkage of cells, membrane integrity distortion, and floatation of cells in culture plates. The morphological changes in the treated irradiated group were indicative of cell death.




Figure 1. Cellular morphological changes in HKESC-1 cells 24 hours post treatments. (A) The morphological changes in the presence of different concentrations of AlPcS₄Cl (without irradiation). (B) The morphological changes of AlPcS₄Cl-PDT at 5 J/cm² irradiation.

3.2. Cellular Proliferation Assay

We evaluated the antiproliferative effects of AlPcS₄Cl-PDT on HKESC-1 cells by measuring the ATP levels, which is a function of cell viability and active cellular proliferative strength. Damage cell membrane results in the ability to produce ATP, and the intracellular ATPases rapidly diminish the ATP in the cytoplasm [7]. The ATP levels were quantified using CellTiter-Glo® 3D luminous assay after incubation with varying concentrations of AlPcS₄Cl (1.25-20 μ M) without irradiation and with irradiation. Our results revealed high ATP levels in non-irradiated cells and active proliferative capabilities both in the control cells and the cell receiving AlPcS₄Cl (Figure 2A). The findings showed that the PS does not affect the proliferation rate of the cancer cells when in an un-activated state.

In contrast, the combination of AlPcS₄Cl with irradiation at 5 J/Cm² significantly showed a dose-dependent reduction of ATP levels and high antiproliferative effects on HKESC-1 cells (***) when compared with the control cells (Figure 2B). This finding is in concordance with the results from

Crous and coworkers, who investigated the effect of AlPcS₄Cl-PDT on lung cancer [6] and Kresfelder et al. (2009) who examined the effects of AlPcSmix on oesophageal cancer [8].




Figure 2. The Antiproliferative effects of AlPcS₄Cl on HKESC-1 cells. (A) Non-irradiated cells showed high levels of ATP and active proliferation with no significant difference between the control cells and cells administered with AlPcS₄Cl. (B) The irradiated cells at 5 J/cm² displayed significant antiproliferative activities with a reduction in ATP levels (***) ($p < 0.001$). The values shown are \pm SEM (standard error of the mean) (n=3).

3.3. Viability

Trypan blue exclusion test was conducted to determine the proportion of live cells present after 24-hour administration of AlPcS₄Cl and AlPcS₄Cl-PDT on HKESC-1 cells. Trypan blue exclusion test is based on the mechanism that the cell membrane integrity of viable cells is intact and therefore expels the Trypan blue dye. In contrast, dead cells retain the stain due to damaged cell membrane [7, 9]. The proportion of live cells was measured using an automated cell counter. The result showed that cells treated with different concentrations of AlPcS₄Cl without irradiation had a high percentage of viable cells which was similar to the untreated control cells (Figure 3A). The findings showed that the PS does not inhibit cell viability in the cancer cells without irradiation. However, substantial differences were seen between the control and the PDT groups, as depicted in Figure 3B ($*p < 0.05$, $***p < 0.001$). The results demonstrated that the PS substantially decreased cell viability rate post-PDT. Comparable findings have been reported on aluminium phthalocyanines based PS on various cancers such as oesophageal cancer [8], lung cancer [6], breast cancer [10], and cervical cancer [11].

3.4. Cytotoxicity

Cytotoxicity assay using lactate dehydrogenase (LDH) release method was employed to quantify the amount of LDH enzyme leakage in the cell culture media. Cells that have damaged cell membrane release LDH, which indicates cytotoxic effects [7, 12]. We found that no statistically significant differences were observed in the non-irradiated (between the control cells and the cells administered with PS) (Figure 4A). Although the non-irradiated cells showed some slight cytotoxic effect compared with the positive control, a common feature of tumour cells undergoing constant proliferation, and so experiencing minor cell death. This observation is consistent with findings from Robertson and colleagues, who examined the cytotoxic effect of metallophthalocyanine (MPc) on human metastatic melanoma cells [13]. The LDH released from damaged cells from the irradiated cells administered with 0–20 μ M of PS at 5 J/cm² were compared to the control receiving no PS and cytotoxicity positive control. The AlPcS₄Cl-PDT induced significant cytotoxicity compared to the control receiving no PS ($*p < 0.05$, $**p < 0.01$) (Figure 4B), which is also in agreement with a study reported by Crous et al. (2019) who investigated the

cytotoxic effect of this PS on lung cancer[6]. In addition, similar results were shown by studies that examined the cytotoxic of AIPcSmix on oesophageal cancer cells [8] and cervical cancer[11].




Figure 3. Fig. 1. Cell viability effect of AIPcS₄Cl ON HKESC-1 using Trypan blue exclusion assay. (A) The percentage of cell viability of non-irradiated cells in different concentrations of AIPcS₄Cl. (B) The percentage of cell viability irradiated with 5 J/cm² after AIPcS₄Cl -PDT treatment. The findings are shown as \pm SEM (n = 3); (*p < 0.05, **p < 0.01, ***p < 0.001).




Figure 4. The cytotoxic effects of AIPcS₄Cl and AIPcS₄Cl-PDT were determined 24 hours after treatments by LDH release cytotoxicity assay on HKESC-1 cells. (A) The levels of LDH leakage in the presence of varying concentrations of AIPcS₄Cl (non-irradiation). (B) The levels of LDH release after AIPcS₄Cl-PDT with 5 J/cm² irradiation. The results are depicted as \pm SEM (n = 3); (*p < 0.05, **p < 0.01).

4. Conclusion

Photodynamic therapy, a non-invasive and non-toxic treatment modality, has emerged as an effective alternative treatment modality required to overcome the challenges associated with the current conventional therapy for various malignancies. Aluminium phthalocyanine and its derivatives have been

investigated in different tumours with promising outcomes. The findings from this study revealed that ALPcS₄Cl mediated PDT can significantly reduce cell viability, inhibit cell proliferation, and have cytotoxic effects on oesophageal cancer. Also, the result showed a negligible dark-cytotoxicity activity on oesophageal cancer, therefore ALPcS₄Cl-PDT offers a promising treatment modality for oesophageal cancer. Further investigation is needed to determine the cell death mechanism and pathways.

Acknowledgements

This research is supported by the South African Research Chairs Initiative of the Department of Science and Technology National Research Foundation of South Africa (Grant No 98337). Onyisi Christiana Didamson has been supported financially by the Global Excellence and Stature, Fourth Industrial Revolution (GES 4.0) Doctoral Scholarship from University of Johannesburg. The authors sincerely thank the University of Johannesburg, the National Laser Centre, and the National Research Foundation of South Africa (CSIR-DST) for their financial grant support.

References

1. Ferlay, J., et al., *Cancer statistics for the year 2020: An overview*. International Journal of Cancer, 2021. **149**(4): p. 778-789.
2. Obermannová, R., et al., *Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up*. Annals of Oncology, 2022.
3. DaSilva, L.L., P.N. Aguiar, Jr, and G. de Lima Lopes, *Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge*. JAMA Oncology, 2021. **7**(11): p. 1613-1614.
4. Didamson, O.C. and H. Abrahamse, *Targeted Photodynamic Diagnosis and Therapy for Esophageal Cancer: Potential Role of Functionalized Nanomedicine*. Pharmaceutics, 2021. **13**(11): p. 1943.
5. Kwiatkowski, S., et al., *Photodynamic therapy - mechanisms, photosensitizers and combinations*. Biomed Pharmacother, 2018. **106**: p. 1098-1107.
6. Crous, A., S.S. Dhillip Kumar, and H. Abrahamse, *Effect of dose responses of hydrophilic aluminium (III) phthalocyanine chloride tetrasulphonate based photosensitizer on lung cancer cells*. J Photochem Photobiol B, 2019. **194**: p. 96-106.
7. Aslantürk, Ö.S., *In vitro cytotoxicity and cell viability assays: principles, advantages, and disadvantages*. Genotoxicity-A predictable risk to our actual world, 2018. **2**: p. 64-80.
8. Kresfelder, T.L., M.J. Cronjé, and H. Abrahamse, *The effects of two metallophthalocyanines on the viability and proliferation of an esophageal cancer cell line*. Photomed. Laser Surg., 2009. **27**(4): p. 625-631.
9. Strober, W., *Trypan Blue Exclusion Test of Cell Viability*. Curr Protoc Immunol, 2015. **111**: p. A3.B.1-a3.B.3.
10. Muehlmann, L.A., et al., *Aluminium-phthalocyanine chloride nanoemulsions for anticancer photodynamic therapy: Development and in vitro activity against monolayers and spheroids of human mammary adenocarcinoma MCF-7 cells*. J Nanobiotechnology, 2015. **13**: p. 36.
11. Chizenga, E.P., R. Chandran, and H. Abrahamse, *Photodynamic therapy of cervical cancer by eradication of cervical cancer cells and cervical cancer stem cells*. Oncotarget, 2019. **10**(43): p. 4380-4396.
12. Riss, T.L., et al. *Cytotoxicity Assays: In Vitro Methods to Measure Dead Cells*. 2019.
13. Robertson, C.A., H. Abrahamse, and D. Evans, *The in vitro PDT efficacy of a novel metallophthalocyanine (MPc) derivative and established 5-ALA photosensitizing dyes against human metastatic melanoma cells*. Lasers Surg Med, 2010. **42**(10): p. 766-76.